Navigate Risk of Ketoacidosis Due to an SGLT2 Inhibitor

December 2023

You’ll need to know how to manage the risk of ketoacidosis due to SGLT2 inhibitors (dapagliflozin, etc)...as their use increases.

Ketoacidosis due to an SGLT2 inhibitor (SGLT2i) is rare...occurring in less than 0.1% of patients.

But it can be life-threatening. And it’s easy to miss, since patients are often euglycemic...with normal or only slightly elevated blood glucose.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote